Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Conjunctiva Inflamed Clear all
Completed Phase 1 Interventional

Systemic Pharmacokinetics of BOL-303224-A

NCT00407589
View directory record Official record
Conditions
Conjunctivitis, Bacterial
Interventions
BOL-303224-A
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis

NCT01877694
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Auriclosene Solution 0.3%, Auriclosene Vehicle
Drug
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Industry
Eligibility
1 Year and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jul 21, 2026, 6:45 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparison of Tolerability Between Two Allergy Drops

NCT01390961
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
alacaftadine and naphazoline HCl & pheniramine maleate
Drug
Lead sponsor
Hom, Milton M., OD, FAAO
Individual
Eligibility
18 Months and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2011 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing

NCT01128556
View directory record Official record
Conditions
Histamine Responsive Allergy Patients
Interventions
Bepreve, Refresh Tears
Drug
Lead sponsor
North Texas Institute for Clinical Trials
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

NCT02634853
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Results available

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

NCT01119287
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution, Inactive ingredients, used as placebo
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years to 64 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Jul 21, 2026, 6:45 AM EDT
Recruiting Not applicable Interventional

RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs)

NCT07322302
View directory record Official record
Conditions
Trachoma, Eye Diseases, Trichiasis
Interventions
B-RAP, BLTR
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

NCT00464438
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
gatifloxacin, moxifloxacin 0.5% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
Up to 31 Days
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle

NCT03489941
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
EM-100, Zaditor®, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Results available

Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya

NCT05918406
View directory record Official record
Conditions
Dry Eye, Keratoconjunctivitis Sicca
Interventions
Nasal Guide
Combination Product
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Edison, New Jersey • Woodland Park, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 1 Interventional

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

NCT01733992
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, R348 Ophthalmic Solution, 1.0%, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 2 Interventional

FST-100 in the Treatment of Acute Adenoviral Conjunctivitis

NCT01470664
View directory record Official record
Conditions
Acute Adenoviral Conjunctivitis
Interventions
FST-100, FST-100 (Component #1), FST-100 Vehicle
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Results available

Moxifloxacin vs. Polytrim for Conjunctivitis

NCT00581542
View directory record Official record
Conditions
Conjunctivitis
Interventions
moxifloxacin, polytrim
Drug
Lead sponsor
University of Rochester
Other
Eligibility
1 Year to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers

NCT06176651
View directory record Official record
Conditions
Dry Eye, Dry Eye, Evaporative, Dry Eye Disease, Evaporative Dry Eye, Evaporative Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions
Miebo
Drug
Lead sponsor
Gordon Schanzlin New Vision
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Jul 21, 2026, 6:45 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo

NCT02998541
View directory record Official record
Conditions
Adenoviral Conjunctivitis
Interventions
SHP640, PVP-I 0.6%, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
68
States / cities
Chandler, Arizona • Glendale, Arizona • Prescott, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome

NCT04206020
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sun City West, Arizona • Andover, Massachusetts • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

NCT01174823
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
bepotastine besilate ophthalmic solution, placebo comparator ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis

NCT00445874
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen with a Contact Lens (no generic name)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Phoenix, Arizona • Irvine, California • North Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis

NCT03320434
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
PRT-2761 0.5%, PRT-2761 1%, Patanol, Pred-forte, PRT-2761 0%
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis

NCT00423007
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bromfenac, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01881113
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

NCT02132169
View directory record Official record
Conditions
Atopic Disease (Including Allergic Conjunctivitis)
Interventions
Drug: AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

NCT05119920
View directory record Official record
Conditions
Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions
Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
19
States / cities
Chandler, Arizona • Sun City, Arizona • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Jul 21, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional

FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis

NCT00941486
View directory record Official record
Conditions
Acute Adenoviral Conjunctivitis
Interventions
FST-100 Ophthalmic Suspension, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
3 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
Torrance, California • Colorado Springs, Colorado • Hamden, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Jul 21, 2026, 6:45 AM EDT